These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35004781)

  • 1. Mortality and Respiratory-Related Hospitalizations in Idiopathic Pulmonary Fibrosis Not Treated With Antifibrotics.
    Cottin V; Spagnolo P; Bonniaud P; Nolin M; Dalon F; Kirchgässler KU; Kamath TV; Van Ganse E; Belhassen M
    Front Med (Lausanne); 2021; 8():802989. PubMed ID: 35004781
    [No Abstract]   [Full Text] [Related]  

  • 2. Antifibrotic therapies reduce mortality and hospitalization among Medicare beneficiaries with idiopathic pulmonary fibrosis.
    Mooney J; Reddy SR; Chang E; Broder MS; Gokhale S; Corral M
    J Manag Care Spec Pharm; 2021 Dec; 27(12):1724-1733. PubMed ID: 34818092
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis.
    Belhassen M; Dalon F; Nolin M; Van Ganse E
    Respir Res; 2021 May; 22(1):135. PubMed ID: 33947414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study.
    Suzuki Y; Mori K; Aono Y; Kono M; Hasegawa H; Yokomura K; Naoi H; Hozumi H; Karayama M; Furuhashi K; Enomoto N; Fujisawa T; Nakamura Y; Inui N; Nakamura H; Suda T
    BMC Pulm Med; 2021 Jul; 21(1):221. PubMed ID: 34247593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications.
    Kelly BT; Thao V; Dempsey TM; Sangaralingham LR; Payne SR; Teague TT; Moua T; Shah ND; Limper AH
    BMC Pulm Med; 2021 Jul; 21(1):239. PubMed ID: 34273943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology, healthcare utilization, and related costs among patients with IPF: results from a German claims database analysis.
    Kreuter M; Picker N; Schwarzkopf L; Baumann S; Cerani A; Postema R; Maywald U; Dittmar A; Langley J; Patel H
    Respir Res; 2022 Mar; 23(1):62. PubMed ID: 35305632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment.
    Noor S; Nawaz S; Chaudhuri N
    Adv Ther; 2021 Jan; 38(1):268-277. PubMed ID: 33098554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Antifibrotic Therapy on Survival in Patients With Idiopathic Pulmonary Fibrosis.
    de Andrade JA; Neely ML; Hellkamp AS; Culver DA; Kim HJ; Liesching T; Lobo LJ; Ramaswamy M; Safdar Z; Bender S; Conoscenti CS; Leonard TB; Palmer SM; Snyder LD;
    Clin Ther; 2023 Apr; 45(4):306-315. PubMed ID: 36997445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disparities in Antifibrotic Medication Utilization Among Veterans With Idiopathic Pulmonary Fibrosis.
    Kaul B; Lee JS; Petersen LA; McCulloch C; Rosas IO; Bandi VD; Zhang N; DeDent AM; Collard HR; Whooley MA
    Chest; 2023 Aug; 164(2):441-449. PubMed ID: 36801465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does continuation of antifibrotics before lung transplantation influence post-transplant outcomes in patients with idiopathic pulmonary fibrosis?
    Zhu MZL; Huang JY; Liu DH; Snell GI
    Interact Cardiovasc Thorac Surg; 2022 Jan; 34(2):250-254. PubMed ID: 34453531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healthcare resource use and associated costs in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis.
    Cottin V; Spagnolo P; Bonniaud P; Dalon F; Nolin M; Kirchgässler KU; Van Ganse E; Belhassen M
    Respir Med Res; 2023 Jun; 83():100951. PubMed ID: 36434913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world retrospective observational study exploring the effectiveness and safety of antifibrotics in idiopathic pulmonary fibrosis.
    Wright WA; Crowley LE; Parekh D; Crawshaw A; Dosanjh DP; Nightingale P; Thickett DR
    BMJ Open Respir Res; 2021 Mar; 8(1):. PubMed ID: 33771813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterizing Health Outcomes in Idiopathic Pulmonary Fibrosis using US Health Claims Data.
    Mortimer KM; Bartels DB; Hartmann N; Capapey J; Yang J; Gately R; Enger C
    Respiration; 2020; 99(2):108-118. PubMed ID: 31982886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
    Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
    BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lung cancer in patients with idiopathic pulmonary fibrosis: A retrospective multicentre study in Europe.
    Karampitsakos T; Spagnolo P; Mogulkoc N; Wuyts WA; Tomassetti S; Bendstrup E; Molina-Molina M; Manali ED; Unat ÖS; Bonella F; Kahn N; Kolilekas L; Rosi E; Gori L; Ravaglia C; Poletti V; Daniil Z; Prior TS; Papanikolaou IC; Aso S; Tryfon S; Papakosta D; Tzilas V; Balestro E; Papiris S; Antoniou K; Bouros D; Wells A; Kreuter M; Tzouvelekis A
    Respirology; 2023 Jan; 28(1):56-65. PubMed ID: 36117239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort.
    Durheim MT; Bendstrup E; Carlson L; Sutinen EM; Hyldgaard C; Kalafatis D; Myllärniemi M; Sköld CM; Sjåheim T
    Respirology; 2021 Oct; 26(10):982-988. PubMed ID: 34291523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifibrotics and lung transplantation: A Spanish multicentre case-controlled study.
    Mora Cuesta VM; Iturbe Fernández D; Aguado Ibáñez S; Anguera de Francisco G; Margallo Iribarnegaray J; Carrillo Hernández-Rubio J; Reig Mezquida JP; Pérez Luz V; Laporta Hernández R; de Pablo Gafas A; Solé Jover A; Cifrián Martínez JM
    Respirology; 2022 Dec; 27(12):1054-1063. PubMed ID: 36053911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Features, Diagnosis, Management, and Outcomes of Idiopathic Pulmonary Fibrosis in Korea: Analysis of the Korea IPF Cohort (KICO) Registry.
    Jegal Y; Park JS; Kim SY; Yoo H; Jeong SH; Song JW; Lee JH; Lee HL; Choi SM; Kim YW; Kim YH; Choi HS; Lee J; Uh ST; Kim TH; Kim SH; Lee WY; Kim YH; Lee HK; Lee EJ; Heo EY; Yang SH; Kang HK; Chung MP;
    Tuberc Respir Dis (Seoul); 2022 Apr; 85(2):185-194. PubMed ID: 34902237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry.
    Snyder L; Neely ML; Hellkamp AS; O'Brien E; de Andrade J; Conoscenti CS; Leonard T; Bender S; Gulati M; Culver DA; Kaner RJ; Palmer S; Kim HJ;
    Respir Res; 2019 May; 20(1):105. PubMed ID: 31142314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry.
    Behr J; Prasse A; Wirtz H; Koschel D; Pittrow D; Held M; Klotsche J; Andreas S; Claussen M; Grohé C; Wilkens H; Hagmeyer L; Skowasch D; Meyer JF; Kirschner J; Gläser S; Kahn N; Welte T; Neurohr C; Schwaiblmair M; Bahmer T; Oqueka T; Frankenberger M; Kreuter M
    Eur Respir J; 2020 Aug; 56(2):. PubMed ID: 32381492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.